Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of macular thickness after cataract surgery with intracameral cefuroxime (hospital-prepared vs Prokam)
2017-001416-11Phase 3Active
- Sponsor
- Parc de Salut Mar
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cefuroxime in Irvine-Gass syndrome (IGS) (2 arms), sponsored by Parc de Salut Mar. Primary endpoints: Macular thickness and Incidence of macular edema. Started Aug 2017; status: active.
02
Drugs
cefuroxime
03
Conditions
Irvine-Gass syndrome (IGS)
Beyond the preview
Go deeper on 2017-001416-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001416-11.